What is Leerink Partnrs’ Estimate for PTGX Q3 Earnings?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities researchers at Leerink Partnrs issued their Q3 2025 earnings estimates for Protagonist Therapeutics in a note issued to investors on Friday, September 12th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.60) for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. Leerink Partnrs also issued estimates for Protagonist Therapeutics’ Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS.

PTGX has been the topic of a number of other reports. Leerink Partners assumed coverage on Protagonist Therapeutics in a research note on Friday. They issued an “outperform” rating and a $73.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a report on Thursday, August 7th. Wall Street Zen raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, June 8th. Finally, JMP Securities raised their target price on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a report on Thursday, August 7th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $67.73.

Protagonist Therapeutics Stock Down 1.4%

Shares of PTGX stock opened at $58.86 on Monday. Protagonist Therapeutics has a fifty-two week low of $33.31 and a fifty-two week high of $61.89. The stock has a market capitalization of $3.66 billion, a P/E ratio of 84.09 and a beta of 2.22. The stock has a 50-day simple moving average of $55.70 and a 200 day simple moving average of $50.87.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. The firm had revenue of $5.55 million during the quarter, compared to analyst estimates of $8.32 million.

Insiders Place Their Bets

In other news, Director William D. Waddill sold 4,000 shares of the company’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $59.25, for a total transaction of $237,000.00. Following the completion of the transaction, the director directly owned 9,130 shares of the company’s stock, valued at $540,952.50. This represents a 30.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 10,415 shares of the company’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $54.78, for a total value of $570,533.70. Following the sale, the chief executive officer owned 520,603 shares in the company, valued at $28,518,632.34. The trade was a 1.96% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,859 shares of company stock valued at $3,687,577. 4.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of large investors have recently modified their holdings of PTGX. GF Fund Management CO. LTD. raised its position in Protagonist Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company’s stock worth $74,000 after purchasing an additional 275 shares during the last quarter. Guggenheim Capital LLC boosted its stake in shares of Protagonist Therapeutics by 1.6% in the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after buying an additional 303 shares during the last quarter. Bessemer Group Inc. grew its stake in Protagonist Therapeutics by 171.0% in the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after buying an additional 318 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Protagonist Therapeutics by 4.1% in the 1st quarter. Hsbc Holdings PLC now owns 8,458 shares of the company’s stock worth $405,000 after purchasing an additional 330 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Protagonist Therapeutics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company’s stock worth $132,000 after purchasing an additional 340 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.